Morgan Stanley analyst Terence Flynn maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of $145.00.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Scientists discover that SARS-CoV-2 spike protein remains in the brain and skull bone marrow for years post-infection, ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

The university filed a lawsuit against BioNTech four months ago, claiming that the company licensed vaccine technology ...

Researchers have discovered that the SARS-CoV-2 spike protein persists in the brain and skull bone marrow for years after ...

Shares of vaccine makers moved higher early Monday following a CDC report that the U.S. was seeing a significant uptick in ...

Russia claims a breakthrough in cancer treatment with a personalized mRNA vaccine, designed to train the immune system to ...

Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of ...

Five years after the start of Covid, we appear to be trying to teach ourselves the lessons of the pandemic the hard way.

The Ohio Department of Health reported that confirmed flu cases in hospitals have increased more than 80% since last week.

ACELYRIN, Inc., a Los Angeles area-based, late-stage clinical biopharma, with additional operations in the San Francisco Bay area, has announced it is acquiring privately held ValenzaBio – which ...